Skip to main content

Advertisement

SpringerLink
Log in

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer

  • Original article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Peritoneal dissemination is a common and fatal clinical manifestation of gastric cancer with few effective therapies available. Natural Newcastle disease virus (NDV) has been shown to be an effective oncolytic agent, and recent advances now allow genetic manipulation of this virus to improve cancer killing and safety. This study was designed to investigate the effectiveness of a genetically engineered NDV in the treatment of peritoneally disseminated gastric carcinoma. NDV mutant virus containing a modified F cleavage site and insertion of enhanced green fluorescent protein (GFP), NDV(F3aa)-GFP, was tested in vitro against human gastric cancer cells by standard cytotoxicity at different multiplicities of infection. To test NDV(F3aa)-GFP in vivo in a peritoneal carcinomatosis gastric tumor model, MKN-74 human gastric cancer cells were injected intraperitoneally (IP) in severe combined immunodeficient mice. Mice were treated with NDV(F3aa)-GFP either once or multiple times after tumor challenge. Effective killing of MKN-74 cells by NDV(F3aa)-GFP was found in vitro. This cancer killing was dose-related and correlated with viral replication. GFP expression was a good marker of infection. The virus was also effective as an antitumor therapy in a peritoneal cancer model that simulates clinical disease. Half the animals treated with virus had no evidence of disease. Genetically engineered NDV [NDV(F3aa)-GFP] administered IP is an effective antitumor therapy against peritoneal carcinomatosis from human gastric cancer in a xenograft model, without significant toxicity. These data provide further rationale for clinical trials involving NDV for peritoneal carcinomatosis from gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Nakajima T (2002) Gastric cancer treatment guidelines in Japan. Gastric Cancer 5:1–5

    Article  PubMed  Google Scholar 

  3. Park CH, Song KY, Kim SN (2008) Treatment results for gastric cancer surgery: 12 years’ experience at a single institute in Korea. Eur J Surg Oncol 34:36–41

    PubMed  CAS  Google Scholar 

  4. Okajima K, Yamada S (1986) Surgical treatment of far-advanced gastric cancer. Jpn J Cancer Clin 32:1203–1209

    CAS  Google Scholar 

  5. Sugarbaker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 58:96–107

    Article  PubMed  CAS  Google Scholar 

  6. Ajani JA, Ota DM, Jackson DE (1991) Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 67:260–265

    Article  PubMed  CAS  Google Scholar 

  7. Donahue JM, Mullen JT, Tanabe KK (2002) Viral oncolysis. Surg Oncol Clin N Am 11:661–680

    Article  PubMed  Google Scholar 

  8. Nemunaitis J (2002) Live viruses in cancer treatment. Oncol Hunt 16:1483–1492

    Google Scholar 

  9. Park MS, García-Sastre A, Cros JF, Basler CF, Palese P (2003) Newcastle disease virus V protein is a determinant of host range restriction. J Virol 77:9522–9532

    Article  PubMed  CAS  Google Scholar 

  10. Nelson NJ (1999) Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 91:1708–1710

    Article  PubMed  CAS  Google Scholar 

  11. Csatary LK (1971) Viruses in the treatment of cancer. Lancet 2(7728):825

    Article  PubMed  CAS  Google Scholar 

  12. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80:5145–5155

    Article  PubMed  CAS  Google Scholar 

  13. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52:448–453

    Article  PubMed  CAS  Google Scholar 

  14. Sergel-Germano T, McQuain C, Morrison TG (1994) Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion. J Virol 68:7654–7658

    PubMed  CAS  Google Scholar 

  15. Park MS, Steel J, García-Sastre A, Swayne D, Palese P (2006) Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 103:8203–8208

    Article  PubMed  CAS  Google Scholar 

  16. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67(17):8285–8292

    Article  PubMed  CAS  Google Scholar 

  17. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62(21):6070–6079

    PubMed  CAS  Google Scholar 

  18. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME (1994) Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54:6017–6021

    PubMed  CAS  Google Scholar 

  19. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86:1228–1233

    Article  PubMed  CAS  Google Scholar 

  20. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ (2001) Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172:27–36

    Article  PubMed  CAS  Google Scholar 

  21. Cassel WA, Murray DR (1992) A ten year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9:169–171

    PubMed  CAS  Google Scholar 

  22. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA (1998) A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4:783–794

    PubMed  CAS  Google Scholar 

  23. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344–1347

    Article  PubMed  CAS  Google Scholar 

  24. Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43:256–264

    Article  PubMed  CAS  Google Scholar 

  25. Ceelen WP, Påhlman L, Mahteme H (2007) Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res 134:195–214

    PubMed  CAS  Google Scholar 

  26. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M (2008) Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 98:273–276

    Article  PubMed  CAS  Google Scholar 

  27. Bennett JJ, Kooby DA, Delman K, McAuliffe P, Halterman MW, Federoff H, Fong Y (2000) Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 78:166–174

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure of potential conflict of interests

The authors declare no conflict of interests related to this study.

Author information

Authors and Affiliations

  1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA

    Kyo Young Song, Joyce Wong, Lorena Gonzalez, Gang Sheng, Dmitriy Zamarin & Yuman Fong

Authors
  1. Kyo Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joyce Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorena Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gang Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dmitriy Zamarin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuman Fong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuman Fong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Song, K.Y., Wong, J., Gonzalez, L. et al. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med 88, 589–596 (2010). https://doi.org/10.1007/s00109-010-0605-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-010-0605-6

Keywords

Search

Navigation